Celltrion Reports Results of CT-P10 (rituximab- biosimilar) in P-III for Advance Follicular Lymphoma (AFL)
Shots:
- The study involves assessing efficacy and safety of CT-P10 vs Rituxan (rituximab) in 140 patients in ratio (1:1) with AFL for a duration of two years
- P-III study results: @ 2 Year OS (93.2% vs 95.3%); PFS (75.2% vs 73.5%); relapse or disease progression (19.4% vs 21.3%); well tolerated and safe- Presented at ASH 2018
- CT-P10 (rituximab- biosimilar) is a mAb for targeting CD20 cells and is approved in EU for NHL- chronic lymphocytic leukemia- RA- granulomatosis with polyangiitis and microscopic polyangiitis
Ref: Celltrion | Image: Celltrion
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com